Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275).
The Eastern Cooperative Oncology Group assessed the activity of diglycoaldehyde (DGA), VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with advanced colorectal cancer. Objective responses were seen in two of 40 evaluable patients receiving methyl-CCNU and beta-2'-deoxythioguanosine and in one of 35 patients receiving DGA. None of 33 patients responded to VP-16-213, but one death related to sepsis and bone marrow failure occurred. Survival of patients whose previous chemotherapy included a nitrosourea was markedly shortened compared to those who had not been exposed to nitrosoureas. With the possible exception of DGA, further treatment of patients with colorectal cancer with these therapies is not warranted.
D000447:Aldehydes / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003849:Deoxyguanosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007288:Inosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D009607:Nitrosourea Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D012673:Semustine / Q000008:administration & dosage*; D013872:Thionucleosides / Q000008:administration & dosage*
D000447:Aldehydes; D009607:Nitrosourea Compounds; D013872:Thionucleosides; D012673:Semustine; D007288:Inosine; D005047:Etoposide; C010438:beta-2'-deoxythioguanosine; D003849:Deoxyguanosine; D011034:Podophyllotoxin